新型Drp1 GTPase 抑制剂,Drpitor1a:在肺高血压中的有效性
Danchen Wu1, Ross D Jansen-van Vuuren2, Asish Dasgupta1
1Department of Medicine (D.W., A.D., R.A.-Q., K.-H.C., A.Y.M., J.D.M., P.C., R.E.T.B., M.M.V., N.M.B., I.M.E., V.S.Y., M.L.O., S.L.A.), Queen's University, Kingston, Ontario, Canada.
Hypertension (Dallas, Tex. : 1979)
|August 20, 2024
概括
Drpitor1a是一种新型的胺相关蛋白1 (Drp1) 抑制剂,有效地减少了肺动脉高血压 (PAH) 细胞中的线粒体裂变和超增殖. 这种药物显示出作为PAH的潜在治疗方法的希望,观察到治疗性变态.
科学领域:
- 线粒体动力学的动态
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺动脉高血压 (PAH) 的特点是肺动脉光滑肌细胞的过度增殖.
- 由胺相关蛋白1 (Drp1) 介导的线粒体裂变增加,有助于这种过度增殖.
- 在PAH中,Drp1抑制剂Drpitor1a的特异性,药理动力学和疗效以前是未知的.
研究的目的:
- 评估Drpitor1a对Drp1 GTPase活性的特异性和抑制作用.
- 在PAH模型中评估Drpitor1a对线粒体分裂,细胞增殖和细胞亡的影响.
- 在PAH大鼠模型中确定Drpitor1a的药理动力学概况和体内疗效.
主要方法:
- 评估了Drpitor1a对复合性和内源性Drp1 GTPase活性的抑制.
- 研究了Drpitor1a对控制中的线粒体分裂和PAH的人类肺动脉光滑肌细胞 (hPASMC) 和血液外生长内皮细胞 (BOEC) 的影响.
- 在hPASMC中评估了细胞增殖和细胞亡,药理动力学,以及在单克罗他林诱导的PAH大鼠模型中的疗效.
主要成果:
- Drpitor1a 特别抑制了 Drp1 GTPase 活性,并逆转了 PAH 细胞中线粒体分裂的增加.
- Drpitor1a在PAH hPASMC中降低了增殖和诱导亡,而不会影响正常细胞中的细胞呼吸或线粒体动力学.
- 在大鼠中,drpitor1a治疗使已建立的单氨酸-PAH回归,没有显著的毒性或全身血管效应.
结论:
- Drpitor1a是一种特定的Drp1 GTPase抑制剂,有效地向PAH中的线粒体裂变.
- Drpitor1a通过减少增殖,诱导PAH细胞中的亡,并在体内逆转PAH来证明治疗潜力.
- Drp1代表了PAH的可行的治疗标,Drpitor1a成为一个有前途的候选药物,表现出显著的治疗性二态.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
138
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
138
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
145
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
145
01:23Antihypertensive Drugs: Vasodilators
492
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
492
01:24Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K